Annexon Biosciences
Annexon Biosciences works on 3 rare diseases tracked on Trial Friend, including Amyotrophic Lateral Sclerosis, Guillain-Barré Syndrome, Huntington Disease.
Annexon Biosciences is a clinical-stage biopharmaceutical company developing therapies that inhibit complement C1q for rare neuroinflammatory and neurodegenerative diseases. The company's lead candidate ANX005 completed Phase 3 for Guillain-Barré syndrome, with a BLA submission expected in 2026 and an EU MAA filed in January 2026. ANX005 is also in Phase 2 for Huntington's disease and ALS. ANX007 targets complement-mediated retinal diseases including geographic atrophy (Phase 3).
Focus areas at Annexon Biosciences
As a rare disease specialist, Annexon Biosciences has active clinical trial programs and drug development efforts across 3 rare diseases, including Amyotrophic Lateral Sclerosis, Guillain-Barré Syndrome, Huntington Disease. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows all active and recruiting studies sponsored by Annexon Biosciences, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Annexon Biosciences is headquartered in Brisbane, United States, founded in 2011, publicly traded under the ticker symbol ANNX. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Active Clinical Trials
FDA-Approved Drugs
Rare Disease Focus Areas (3)
Diseases targeted by Annexon Biosciences's clinical trial and drug development programs
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease destroying motor neurons in the brain and spinal cord. This causes progressive weakness and paralysis of voluntary muscles whil...
Guillain-Barré syndrome is a rare autoimmune neurological disorder in which the body's immune system attacks the peripheral nerves, causing rapidly progressive muscle weakness that typically starts in...
Huntington disease is an autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the huntingtin gene. The progressive disease causes movement problems, cognitiv...
Patient Resources
Organizations and resources related to Annexon Biosciences's rare disease focus areas
Frequently Asked Questions About Annexon Biosciences
Common questions about Annexon Biosciences's rare disease programs, clinical trials, and treatments.